EX-99.1 2 abbv-20221231nonxgaapxex991.htm EX-99.1

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended December 31, 2022																		Full-Year Ended December 31, 2022
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q4 2022 acquired IPR&D and milestones expense			$	—					$	3.65					$	3.69					$	454					$	13.84					$	13.88
Q4 2022 acquired IPR&D and milestones expense			243						(0.14)						(0.14)						243						(0.14)						(0.14)
Guidance including Q4 2022 acquired IPR&D and milestones expense			$	243					$	3.51					$	3.55					$	697					$	13.70					$	13.74

    1